Shares of Pfizer Inc. PFE advanced 1.26% to $26.43 Friday, on what proved to be an all-around favorable trading session for ...

Pfizer made changes to its DEI webpage, joining other companies across different industries repositioning their messaging ...

Revolving door is a VERY polite term for Patrizia Cavazzoni's moves. Then again, she has a 25-year history of picking Big ...

Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief ...

A study by KFF found that one in four Republican parents now say they've skipped or delayed some childhood vaccines as of ...

Shares of Pfizer Inc. PFE slid 1.20% to $26.42 Wednesday, on what proved to be an all-around mixed trading session for the ...

Pfizer Inc. appointed the Food and Drug Administration’s former top drug reviewer to serve as its chief medical officer.

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

Bernstein lowered the firm’s price target on Pfizer (PFE) to $30 from $32 and keeps a Market Perform rating on the shares. The firm notes ...

Medicare changes will cut $1 billion from 2025 revenue, with Pfizer now responsible for 20% of catastrophic drug costs. Read ...

We can refer to full-year 2019 revenue of about $51 billion and the company's comments about potential revenue of more than ...

Britain's health regulator said on Friday it has approved Moderna's vaccine for respiratory syncytial virus in adults 60 ...